UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $209.45 Million Holdings in TransMedics Group, Inc. $TMDX

Key Points

• UBS AM significantly increased its stake in TransMedics Group, Inc. by 244.7% in Q1, holding over 3 million shares valued at approximately $209 million.
• Several other institutional investors have also strengthened their positions, contributing to a total institutional ownership of 99.67% of the company's stock.
• TransMedics reported Q2 earnings of $0.92 per share, well exceeding estimates, and a revenue of $157.37 million, reflecting a 37.7% year-over-year increase.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 244.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,113,082 shares of the company's stock after buying an additional 2,209,996 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 9.20% of TransMedics Group worth $209,448,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Goldman Sachs Group Inc. increased its stake in shares of TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock worth $34,145,000 after purchasing an additional 86,721 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company's stock worth $1,314,000 after purchasing an additional 868 shares during the last quarter. Royal Bank of Canada increased its stake in shares of TransMedics Group by 47.9% during the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company's stock worth $1,788,000 after purchasing an additional 8,604 shares during the last quarter. Quarry LP increased its stake in shares of TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after purchasing an additional 278 shares during the last quarter. Finally, Driehaus Capital Management LLC increased its stake in shares of TransMedics Group by 2.4% during the 1st quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company's stock worth $52,395,000 after purchasing an additional 17,913 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Price Performance

TMDX stock traded up $1.65 during trading on Wednesday, hitting $120.80. 157,140 shares of the stock traded hands, compared to its average volume of 1,295,523. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The stock has a market cap of $4.12 billion, a price-to-earnings ratio of 62.59 and a beta of 2.18. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $169.29. The company has a 50 day simple moving average of $115.82 and a 200 day simple moving average of $106.11.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company's quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. Equities analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group raised their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Stifel Nicolaus assumed coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They issued a "hold" rating and a $115.00 target price on the stock. Piper Sandler reiterated an "overweight" rating and issued a $145.00 target price (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Wall Street Zen lowered shares of TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday, August 30th. Finally, Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $125.40.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.